SYSTEM AND METHOD FOR RHYTHM IDENTIFICATION AND THERAPY DISCRIMINATION USING HEMODYNAMIC STATUS INFORMATION

• US 20100305635A1
• Filed: 05/24/2010
• Published: 12/02/2010
• Est. Priority Date: 05/26/2009
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Gilkerson, James O., Li, Dan, Shuros, Allan C., Liu, Lili
• Application Number:
  US12/786,074
• Publication Number:
  US 20100305635A1
• Time in Patent Office: Days
• US Class Current: 607/6
• CPC Class Codes: A61B 5/02028 Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/36564 controlled by blood pressure
• CPC Class Codes: A61N 1/36585 controlled by two or more physical parameters
• CPC Class Codes: A61N 1/39622 Pacing therapy

Abstract

A system and method for controlling cardiac ventricular tachyarrhythmias by acquiring a pressure signal representative of coronary venous pressure (CVP) from a pressure sensor implanted within a coronary vein of the patient. A CVP index is derived based on the pressure signal. The onset of a ventricular tachyarrhythmia episode is detected based on a cardiac rates signal. The CVP index and the rate signal are monitored and, responsive to the rate signal indicating a sustained tachycardia episode during the episode monitoring period, anti-tachycardia therapy selectively withheld and the episode monitoring period is extended based on the CVP index.

Claims

1. A method for controlling cardiac ventricular tachyarrhythmias using an implanted medical device, the method comprising the implanted medical device:

acquiring a pressure signal representative of coronary venous pressure (CVP) from a pressure sensor implanted within a coronary vein of the patient, and deriving a CVP index based on the pressure signal;

acquiring a rate signal indicative of the patient'"'"'s cardiac rate from an implanted rate sensor;

detecting an onset of a ventricular tachyarrythmia (VT) episode based on the rate signal;

monitoring the rate signal and the CVP index for an episode monitoring period; and

responsive to the rate signal indicating a sustained tachycardia episode during the episode monitoring period, selectively withholding anti-tachycardia therapy and extending the episode monitoring period based on the CVP index.

2. The method of claim 1 wherein withholding anti-tachycardia therapy and extending the episode monitoring period includes withholding anti-tachycardia therapy and extending the episode monitoring period in response to the CVP index indicating a hemodynamically stable VT episode.

3. The method of claim 1 further comprising selectively delivering anti-tachycardia therapy or withholding anti-tachycardia therapy based on the CVP index.

4. The method of claim 3 wherein selectively applying the anti-tachycardia therapy includes applying an anti-tachycardia therapy in response to the CVP index indicating a moderately hemodynamically unstable VT episode.

5. The method of claim 1 further comprising applying a defibrillation shock during the episode monitoring period in response to the CVP index indicating a hemodynamically unstable VT episode.

6. The method of claim 1 further comprising, responsive to the rate signal indicating a sustained tachycardia episode, applying anti-tachycardia therapy when a duration of the episode monitoring period equals or exceeds a predetermined maximum episode duration.

7. The method of claim 1 wherein the CVP index is a relative change in a sensed average CVP relative to a baseline average CVP.

8. The method of claim 1 wherein the anti-tachycardia therapy is an anti-tachycardia pacing therapy.

9. The method of claim 1 wherein the anti-tachycardia therapy is a defibrillation shock.

10. A method for controlling cardiac ventricular tachyarrhythmias using an implanted medical device, the method comprising the implanted medical device:

acquiring a pressure signal representative of CVP from a pressure sensor implanted within a coronary vein of the patient, and deriving a CVP index based on the pressure signal;

acquiring a rate signal indicative of the patient'"'"'s cardiac rate from an implanted rate sensor;

detecting an onset of a VT episode based on the rate signal;

monitoring the rate signal and the CVP index for an episode monitoring period;

classifying the VT episode according to a degree of hemodynamic stability or hemodynamic instability based on the CVP index;

delivering an anti-tachycardia therapy if the episode is classified as hemodynamically unstable; and

withholding anti-tachycardia therapy and extending the episode monitoring period if the episode is classified as hemodynamically stable.

11. The method of claim 10 wherein classifying the VT episode is performed upon expiration of the episode monitoring period in response to the VT episode being a sustained episode.

12. The method of claim 10 wherein classifying the VT episode includes classifying the VT episode as hemodynamically stable, moderately hemodynamically unstable, or highly hemodynamically unstable.

13. The method of claim 10 wherein classifying the VT episode includes classifying the VT episode as being associated with a first or second degree of hemodynamic instability.

14. The method of claim 13 wherein delivering the anti-tachycardia therapy if the episode is classified as hemodynamically unstable includes applying a first anti-tachycardia therapy if the VT episode is classified as being associated with the first degree of hemodynamic instability, and applying a second anti-tachycardia therapy if the VT episode is classified as being associated with the second degree of hemodynamic instability.

15. The method of claim 10 further comprising applying a defibrillation shock during the episode monitoring period in response to the CVP index indicating a hemodynamically unstable VT episode.

16. The method of claim 10 further comprising, responsive to the rate signal indicating a sustained tachycardia episode, applying anti-tachycardia therapy when a duration of the episode monitoring period equals or exceeds or equals a predetermined maximum episode duration.

17. The method of claim 16 wherein the predetermined maximum episode duration is selected based on the CVP index.

18. An implantable cardiac rhythm management system comprising:

a plurality of implantable medical electrical leads configured to sense cardiac electrical activity and to deliver an electrical therapeutic stimulus to cardiac tissue, at least one of the leads being configured for chronic implantation within a coronary vein of the patient'"'"'s heart and including a pressure sensor configured to generate a pressure signal indicative of fluid pressure within the coronary vein;

an implantable pulse generator operatively coupled to the leads configured to generate the electrical therapeutic stimulus, the pulse generator including a control system configured to;

acquire the pressure signal and derive a CVP index based on the pressure signal;

acquire a rate signal indicative of the patient'"'"'s cardiac rate from at least one of the implantable leads;

detect an onset of a VT episode based on the rate signal;

monitor the rate signal and the CVP index for an episode monitoring period; and

classify the VT episode as hemodynamically stable or hemodynamically unstable based on the CVP index;

deliver an anti-tachycardia therapy if the episode is determined to be hemodynamically unstable; and

withhold anti-tachycardia therapy and extending the episode monitoring period if the episode is determined to be hemodynamically stable.

19. The system of claim 18 wherein the control system is further configured to assign a maximum duration to the episode monitoring period based on the CVP index.

20. The system of claim 18 wherein the control system is configured to select the anti-tachycardia therapy based on a degree of hemodynamic instability associated with the VT episode as indicated by the CVP index.